Table 3.
The PD-MBC values for compounds 3, 4, and MB against 16 MRSA strains.
| MRSA Type | MRSA Strain | Compound 3 | Compound 4 | MB | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PDT (µM) | No PDT (µM) | aPDT potencya | PDT (µM) | No PDT (µM) | PDT (µM) | No PDT (µM) | aPDTpotency | |||
| ATCC | 43300 | 12.5 | 100b - > 100 | 8 - >8 | >100 | >100 | 625 | >2500c | >4 | |
| ATCC | BAA 42 | 12.5 - 25 | > 100 | 4 - 8 | >100 | >100 | 625 | >2500 | >4 | |
| ATCC | BAA 43 | 25-50 | > 100 | 2 - >4 | >100 | >100 | 312.5-625 | >2500 | 4->8 | |
| ATCC | BAA 44 | 12.5 - 25 | 100 | 4 - 8 | >100 | >100 | 312.5-625 | >2500 | 4->8 | |
| Mutant | AAC(6’)-APH(2’’) | 6.25 | 100 | 16 | >100 | >100 | 625-1250 | >2500 | 2->4 | |
| Mutant | RN4220/pUL5054 | 12.5 - 25 | 100 - > 100 | 4 - >8 | >100 | >100 | 1250-2500 | >2500 | 2->4 | |
| CAd | W44 | 6.25 - 12.5 | 100 - > 100 | 8 - >16 | >100 | >100 | 2500 | >2500 | >1 | |
| CA | W45 | 12.5 - 50 | > 100 | 2 - >8 | >100 | >100 | 1250-2500 | >2500 | 1->2 | |
| CA | W46 | 25 - 50 | > 100 | 2 - >4 | >100 | >100 | 2500 | >2500 | >1 | |
| CA | W47 | 3.125 - 6.25 | > 100 | 16 - >32 | >100 | >100 | 2500 | >2500 | >1 | |
| CA | W48 | 3.125 - 12.5 | > 100 | 8 - >32 | >100 | >100 | 2500 | >2500 | >1 | |
| HAe | W231 | 1.56 - 6.25 | > 100 | 16 - >64 | >100 | >100 | 2500 | >2500 | >1 | |
| HA | W232 | 3.125 - 6.25 | > 100 | 16 - >32 | >100 | >100 | 2500 | >2500 | >1 | |
| HA | W233 | 6.25 | > 100 | > 16 | >100 | >100 | 2500 | >2500 | >1 | |
| HA | W234 | 12.5 | > 100 | >8 | >100 | >100 | 2500 | >2500 | >1 | |
| HA | W235 | 1.56 - 3.125 | > 100 | 32 - >64 | >100 | >100 | 2500 | >2500 | >1 | |
aFold reduction in compound 3, 4 and MB concentration, relative to dark toxicity (no light exposure); bHighest concentration tested for compound 3 and 4; cHighest concentration tested for MB; dCommunity-associated; eHospital-associated.